(Difference between revisions)
UrbanB (Talk | contribs)
(Created page with "<html> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge" /> <style type="text/css"> #container {background:#fff; margin:0 auto 0px; padding:5px 0px 0px; width:960px;...")
Newer edit →

Revision as of 09:14, 26 September 2012


We have considered as examples for the proof of principle two different diseases that could be treated by the use of our synthetic microencapsulated cellular device (Figure 1):

  • The therapy of hepatitis C by the local production of interferon alpha followed by the production of hepatocyte growth factor, providing a regeneration step.
  • The therapy of ischaemic heart disease with anakinra as an antiinflammatory agent, while vascular endothelial growth factor and platelet-derived growth factor, produced in stoichiometric amounts enhance angiogenesis and tissue oxigenation.

Next: Hepatitis C >>